Engineered mesenchymal stem cells for premature ovarian insufficiency: Targeted strategies to overcome clinical translation bottlenecks (Review)
International Journal of Molecular Medicine · 20.11.2026 · 59 (1) · 1-20
DOI: 10.3892/ijmm.2026.6062 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 20.11.2026. Verfasst von Qi Cao und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Premature ovarian insufficiency (POI) is defined as the decline of ovarian function before the age of 40 years, leading to loss of fertility and long‑term health damage. Currently, there is no treatment that can restore endogenous ovarian function. The ability of mesenchymal stem cells (MSCs) to repair ovarian function through paracrine signaling pathways has been demonstrated in preclinical studies; however, inconsistent clinical efficacy hinders their widespread application. This inconsistency originates from four well‑defined biological bottlenecks: i) Poor homing efficiency; ii) short survival time in the damaged microenvironment; iii) marked functional heterogeneity of cell populations; and iv) an unclear dose‑effect relationship. Over the years, based on an in‑depth understanding of MSC biology, engineered targeting strategies addressing the aforementioned bottlenecks have achieved systematic breakthroughs, including genetic modification to enhance homing capacity, preconditioning and three‑dimensional culture to prolong cell survival, functional subpopulation selection to improve efficacy consistency and biomaterial scaffolds to optimize local delivery. Notably, combined application of multiple strategies has shown synergistic effects in POI animal models. Early‑phase clinical studies have preliminarily confirmed the safety and feasibility of engineered MSC therapies; nevertheless, clinical translation still faces challenges such as large‑scale production of engineered products, validation of potency markers and long‑term safety monitoring. The present review systematically summarizes the research progress of these targeting strategies, aiming to provide a theoretical basis for establishing standardized and reproducible engineered MSC therapeutic protocols, and to promote the evolution of POI treatment from empirical attempts towards precision medicine.
Zitieren
APA
Cao, Q., Luo, X., Guo, X., Jia, Q., Yao, J., Mi, W., & Tian, T. (2026). Engineered mesenchymal stem cells for premature ovarian insufficiency: Targeted strategies to overcome clinical translation bottlenecks (Review). International Journal of Molecular Medicine, 59(1), 1-20. https://doi.org/10.3892/ijmm.2026.6062
Vancouver
Cao Q, Luo X, Guo X, Jia Q, Yao J, Mi W, et al. Engineered mesenchymal stem cells for premature ovarian insufficiency: Targeted strategies to overcome clinical translation bottlenecks (Review). International Journal of Molecular Medicine. 2026;59(1):1-20. doi:10.3892/ijmm.2026.6062
BibTeX
@article{Cao2026,
author = {Cao, Qi and Luo, Xiunan and Guo, Xiangyu and Jia, Qingge and Yao, Juncheng and Mi, Wenyi and Tian, Tian},
title = {Engineered mesenchymal stem cells for premature ovarian insufficiency: Targeted strategies to overcome clinical translation bottlenecks (Review)},
journal = {International Journal of Molecular Medicine},
year = {2026},
volume = {59},
number = {1},
pages = {1--20},
doi = {10.3892/ijmm.2026.6062}
}
EUVIMED